Amgen 2007 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2007 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

General medicine
Pipeline
Phase 1 clinical trials investigate safety and proper dose
ranges of a product candidate in a small number of
human subjects.
Phase 2 clinical trials investigate side effect profiles and
efficacy of a product candidate in a large number of
patients who have the disease or condition under study.
For more information on our pipeline, please visit www.amgen.com or refer to Amgen’s most recent Form 10-K, included as part of this publication. For important safety information about Amgen
medicines, please visit www.amgen.com for links to the product websites. This table is as of February 27, 2008, and shows the status and certain next-expected milestones of selected clinical programs
and molecules in Amgen’s product pipeline. Amgen’s product pipeline will change over time as programs and molecules move through the drug development process, including progressing to market or
4
Therapeutic Areas
Inflammation
Metabolic disorders
Neuroscience
Oncology
Bone
rhApo2L/TRAIL
Various cancer types
Panitumumab
Locally advanced head and neck cancer
Motesanib diphosphate
Thyroid cancer
Romiplostim
Myelodysplastic syndromes
Romiplostim (formerly AMG 531)
Chemotherapy-induced thrombocytopenia in non-small cell
lung cancer and lymphoma
AMG 655
Various cancer types
AMG 479
Various cancer types
AMG 386
Various cancer types
AMG 102
Various cancer types
Denosumab
Multiple myeloma
Motesanib diphosphate
First-line breast cancer
AMG 223
Hyperphosphatemia
AMG 222
Type 2 diabetes
Cinacalcet HCl
Primary hyperparathyroidism
AMG 108
Rheumatoid arthritis
AMG 317
Asthma
Denosumab
Rheumatoid arthritis
AMG 379
Pain
AMG 221
Type 2 diabetes
AMG 477
Type 2 diabetes
AMG 557
Systemic lupus erythematosus
AMG 811
Systemic lupus erythematosus
AMG 714
Psoriasis
AMG 853
Asthma
AMG 827
Rheumatoid arthritis
Sclerostin Ab (AMG 785)
Bone loss
AMG 745
Muscle wasting disorders